NasdaqCM - Delayed Quote USD

NuCana plc (NCNA)

3.9900 +0.2100 (+5.56%)
At close: April 22 at 4:00 PM EDT
3.8100 -0.18 (-4.51%)
After hours: April 22 at 6:41 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Hugh Stephen Griffith Founder, CEO & Executive Director 1.21M -- 1968
Mr. Donald Munoz Chief Financial Officer -- -- 1969
Mr. David Harrison Head of Translational Medicine -- -- 1960
Dr. Jeffrey D. Bloss F.A.C.O.G., M.D. Chief Medical Officer -- -- 1958
Ms. Theresa Bruce Senior Vice President of Clinical Operations -- -- --
Ms. Elisabeth Oelmann Senior Vice President of Medical & Clinical Development -- -- --
Martin Quinn Company Secretary -- -- --

NuCana plc

3 Lochside Way
Edinburgh, EH12 9DT
United Kingdom
44 13 1357 1111 https://www.nucana.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
25

Description

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Corporate Governance

NuCana plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 15, 2024 - May 20, 2024
NuCana plc Earnings Call

Related Tickers

TCON TRACON Pharmaceuticals, Inc.
1.8200
-7.14%
 
ALLR Allarity Therapeutics, Inc.
1.4200
+2.16%
 
KTRA Kintara Therapeutics, Inc.
0.1143
-5.85%
 
ZVSA ZyVersa Therapeutics, Inc.
0.5748
-2.74%
 
SNGX Soligenix, Inc.
0.4058
-5.85%
 
WINT Windtree Therapeutics, Inc.
5.45
-11.42%
 
ALRN Aileron Therapeutics, Inc.
4.7500
+0.21%
 
BPTH Bio-Path Holdings, Inc.
2.9200
-31.93%
 
PXMD PaxMedica, Inc.
0.7523
-1.13%
 
NRXP NRx Pharmaceuticals, Inc.
3.0000
-1.32%